Lifordi Immunotherapeutics
Latest round
- Series A
Last raised
- Sep 2024
Total raised
- $70M
Investors
- 3
About Lifordi Immunotherapeutics
Founded in 2023 in Burlington, US, Lifordi Immunotherapeutics specializes in creating targeted therapies for autoimmune diseases. The company has completed one deal as of November 19, 2025, indicating a strategic approach to developing its product pipeline.Lifordi specializes in developing targeted antibody-drug conjugates (ADCs) aimed at treating autoimmune and inflammatory disorders. Their core product offering, LFD-200, is currently undergoing a Phase 1 clinical trial for rheumatoid arthritis, demonstrating the company’s commitment to innovative therapeutic solutions that address significant unmet medical needs. The targeted ADC platform functions by delivering cytotoxic agents directly to diseased cells, maximizing therapeutic efficacy while minimizing systemic toxicity.Lifordi's revenue generation strategy centers around partnerships and collaborations with healthcare institutions and pharmaceutical companies, focusing on the commercialization of their ADC therapies. The business model typically involves agreements for co-development and distribution, where partners may share costs and revenues from successful product launches. Specific transaction structures include B2B arrangements with obligations for milestone payments and royalties based on product sales. Lifordi aims to expand its product line with additional ADC therapies targeting various autoimmune conditions while increasing its market presence in North America and Europe by 2026.
Who invested in Lifordi Immunotherapeutics
3 investors across 1 round
See all investors in Lifordi Immunotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 27, 2024
Amount
$70M
Investors
Questions about Lifordi Immunotherapeutics
Who invested in Lifordi Immunotherapeutics?
Lifordi Immunotherapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lifordi Immunotherapeutics raised?
Lifordi Immunotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Lifordi Immunotherapeutics last raise money?
Lifordi Immunotherapeutics's most recent round on record is a Series A, in Sep 2024.
What does Lifordi Immunotherapeutics do?
Founded in 2023 in Burlington, US, Lifordi Immunotherapeutics specializes in creating targeted therapies for autoimmune diseases.
Where is Lifordi Immunotherapeutics headquartered?
Lifordi Immunotherapeutics is headquartered in Burlington, US.
Which VCs invest in companies like Lifordi Immunotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Lifordi Immunotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Lifordi Immunotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.